AI Engines For more Details: Perplexity Kagi Labs You
Cognitive Impairment: Zonisamide can cause cognitive side effects such as confusion, difficulty concentrating, memory problems, and impaired attention. These effects may be more pronounced at higher doses or in elderly individuals.
Sedation and Fatigue: Zonisamide may cause sedation, drowsiness, lethargy, and fatigue, particularly during the initial titration period or when taken in combination with other central nervous system depressants.
Psychiatric Symptoms: Some individuals may experience psychiatric side effects such as mood changes, irritability, agitation, depression, anxiety, and suicidal thoughts or behavior while taking zonisamide. Close monitoring is recommended, especially in patients with pre-existing psychiatric conditions.
Gastrointestinal Disturbances: Zonisamide can cause gastrointestinal side effects such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. These symptoms are usually mild to moderate in severity and may improve over time.
Weight Loss: Zonisamide has been associated with weight loss as a side effect, which may be desirable in some individuals but can be concerning in others, particularly those who are underweight or at risk of malnutrition.
Renal Stones: Long-term use of zonisamide may increase the risk of kidney stones (renal calculi) due to the medication's effect on urinary pH and electrolyte balance. Patients are advised to maintain adequate hydration and undergo periodic monitoring of renal function and urinary parameters.
Oligohidrosis and Hyperthermia: Rarely, zonisamide can cause decreased sweating (oligohidrosis) and increased body temperature (hyperthermia), particularly in hot weather or during vigorous physical activity. This can potentially lead to heat-related illnesses such as heatstroke.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 4 | 0.3 | 12.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.1 | 2.3 | -0.1 |
| Allergies | 4.3 | 2.2 | 0.95 |
| Allergy to milk products | 2.2 | 1.6 | 0.38 |
| Alopecia (Hair Loss) | 0.4 | 0.4 | |
| Alzheimer's disease | 4.3 | 6 | -0.4 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.6 | 1.3 | 1 |
| Ankylosing spondylitis | 2.9 | 0.6 | 3.83 |
| Anorexia Nervosa | 1.4 | 2.5 | -0.79 |
| Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
| Asthma | 3.6 | 2.9 | 0.24 |
| Atherosclerosis | 2 | 1.1 | 0.82 |
| Atrial fibrillation | 3 | 1.9 | 0.58 |
| Autism | 5.5 | 6.6 | -0.2 |
| Autoimmune Disease | 1.2 | 0.8 | 0.5 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.2 | 1.2 | |
| Bipolar Disorder | 1.6 | 1.4 | 0.14 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.5 | 0.5 | |
| Cancer (General) | 0.6 | 2 | -2.33 |
| Carcinoma | 2.9 | 2 | 0.45 |
| Celiac Disease | 2.2 | 2.7 | -0.23 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 2.8 | 2.9 | -0.04 |
| Chronic Kidney Disease | 2.9 | 2 | 0.45 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 1.4 | 0.07 |
| Chronic Urticaria (Hives) | 1.7 | 0.9 | 0.89 |
| Coagulation / Micro clot triggering bacteria | 1.8 | 1.3 | 0.38 |
| Cognitive Function | 2.2 | 1.4 | 0.57 |
| Colorectal Cancer | 5.3 | 2.2 | 1.41 |
| Constipation | 1.2 | 0.7 | 0.71 |
| Coronary artery disease | 2.3 | 2.5 | -0.09 |
| COVID-19 | 6.3 | 6.3 | 0 |
| Crohn's Disease | 5.5 | 4.3 | 0.28 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.1 | 1.8 | -0.64 |
| d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
| deep vein thrombosis | 2 | 1.4 | 0.43 |
| Denture Wearers Oral Shifts | 0.7 | 0.7 | |
| Depression | 7.5 | 7.6 | -0.01 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.2 | 1.6 | -0.33 |
| Endometriosis | 2.8 | 2.2 | 0.27 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 3 | 2.1 | 0.43 |
| erectile dysfunction | 0.9 | 0.3 | 2 |
| Fibromyalgia | 1.6 | 1 | 0.6 |
| Functional constipation / chronic idiopathic constipation | 4.5 | 3.6 | 0.25 |
| gallstone disease (gsd) | 2.7 | 1.1 | 1.45 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.6 | 0.17 |
| Generalized anxiety disorder | 2.4 | 1.9 | 0.26 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.2 | 0.5 | 3.4 |
| Graves' disease | 1.9 | 2.7 | -0.42 |
| Gulf War Syndrome | 0.7 | 1.4 | -1 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.8 | 1.2 | 1.33 |
| Heart Failure | 2.7 | 1.8 | 0.5 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.3 | 1 |
| High Histamine/low DAO | 1.1 | 0.6 | 0.83 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.5 | 0.6 |
| hyperglycemia | 2.1 | 1.9 | 0.11 |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.3 | 1.67 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.9 | 4.7 | -0.21 |
| Hypothyroidism | 0.2 | 0.7 | -2.5 |
| Hypoxia | 2.4 | 0.3 | 7 |
| IgA nephropathy (IgAN) | 1.3 | 2 | -0.54 |
| Inflammatory Bowel Disease | 4.6 | 6.7 | -0.46 |
| Insomnia | 1.4 | 2.9 | -1.07 |
| Intelligence | 1.4 | 1.4 | |
| Intracranial aneurysms | 1.2 | 0.6 | 1 |
| Irritable Bowel Syndrome | 5.9 | 4.3 | 0.37 |
| ischemic stroke | 3 | 1.7 | 0.76 |
| Liver Cirrhosis | 6.2 | 4.1 | 0.51 |
| Long COVID | 4.3 | 5.1 | -0.19 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.2 | 0.9 | 0.33 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 0.3 | 1 | -2.33 |
| ME/CFS without IBS | 0.3 | 0.6 | -1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.5 | 0.8 | 0.88 |
| Metabolic Syndrome | 5.8 | 6.6 | -0.14 |
| Mood Disorders | 7.7 | 6.2 | 0.24 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 3.7 | 3.2 | 0.16 |
| Multiple system atrophy (MSA) | 1.4 | 0.7 | 1 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 2.8 | -2.8 | |
| Neuropathy (all types) | 0.7 | 1.8 | -1.57 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.5 | 4.5 | -0.29 |
| NonCeliac Gluten Sensitivity | 1.5 | 0.6 | 1.5 |
| Obesity | 8.2 | 6 | 0.37 |
| obsessive-compulsive disorder | 3.7 | 2.7 | 0.37 |
| Osteoarthritis | 1.7 | 1.4 | 0.21 |
| Osteoporosis | 2 | 1.2 | 0.67 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 6.7 | 4.1 | 0.63 |
| Polycystic ovary syndrome | 4.1 | 2.4 | 0.71 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.6 | 0.9 | -0.5 |
| Primary sclerosing cholangitis | 1.6 | 1.5 | 0.07 |
| Psoriasis | 2.7 | 2.3 | 0.17 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.6 | 3.1 | 0.48 |
| Rosacea | 0.9 | 0.5 | 0.8 |
| Schizophrenia | 4.9 | 2.8 | 0.75 |
| scoliosis | 0.8 | 0.3 | 1.67 |
| Sjögren syndrome | 2.3 | 2.3 | 0 |
| Sleep Apnea | 1 | 1.6 | -0.6 |
| Slow gastric motility / Gastroparesis | 1.4 | 0.3 | 3.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 0.5 | 2.4 |
| Stress / posttraumatic stress disorder | 2.3 | 2.6 | -0.13 |
| Systemic Lupus Erythematosus | 3 | 1.6 | 0.88 |
| Tic Disorder | 0.9 | 0.6 | 0.5 |
| Tourette syndrome | 0.5 | 0.3 | 0.67 |
| Type 1 Diabetes | 3.3 | 3.1 | 0.06 |
| Type 2 Diabetes | 6.2 | 5.7 | 0.09 |
| Ulcerative colitis | 3.2 | 4.7 | -0.47 |
| Unhealthy Ageing | 1.9 | 2.4 | -0.26 |
| Vitiligo | 2 | 1.1 | 0.82 |
